WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205745
CAS#: 1246203-36-0 (mesylate)
Description: PWT33597, also known as VDC-597, is an orally bioavailable dual inhibitor of phosphatidylinositide 3-kinase (PI3K) alpha and mammalian target of rapamycin (mTOR) kinase with potential antineoplastic activity. PI3K alpha/mTOR dual inhibitor PWT33597 selectively inhibits both PI3K alpha kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in PI3K/mTOR-overexpressing tumor cells.
MedKoo Cat#: 205745
Name: PWT33597 mesylate
CAS#: 1246203-36-0 (mesylate)
Chemical Formula: C27H34F2N8O7S2
Molecular Weight: 684.7348
Elemental Analysis: C, 47.36; H, 5.01; F, 5.55; N, 16.36; O, 16.36; S, 9.36
PWT33597 mesylate is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to email@example.com to inquire quote.
Related CAS #: 1246203-32-6 (free base) 1246203-36-0 (mesylate)
Synonym: PWT33597 ; PWT 33597; PWT33597; VDC-597; VDC597; VDC 597; PWT33597 mesylate
IUPAC/Chemical Name: N-(4-(4-(2-(difluoromethyl)-4-methoxy-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-2-(dimethylamino)ethane-1-sulfonamide mesylate
InChi Key: XSLUGEGXPCDRTN-UHFFFAOYSA-N
InChi Code: InChI=1S/C26H30F2N8O4S.CH4O3S/c1-34(2)13-16-41(37,38)33-18-9-7-17(8-10-18)23-30-25(35-11-14-40-15-12-35)32-26(31-23)36-19-5-4-6-20(39-3)21(19)29-24(36)22(27)28;1-5(2,3)4/h4-10,22,33H,11-16H2,1-3H3;1H3,(H,2,3,4)
SMILES Code: O=S(CCN(C)C)(NC1=CC=C(C2=NC(N3C(C(F)F)=NC4=C(OC)C=CC=C34)=NC(N5CCOCC5)=N2)C=C1)=O.OS(=O)(C)=O
The following data is based on the product molecular weight 684.7348 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
PWT33597 is currently being developed by Pathyway Theraceuptics, which demonstrates excellent in vitro selectivity for its targets, with negligible activity against other lipid kinases, protein kinases and other pharmacologically relevant targets at biologically active concentrations. The compound achieves good distribution into tumors, robust pathway inhibition and excellent oral efficacy in multiple xenograft across varying genetic backgrounds. PWT33597 has an excellent DMPK and safety profile and is an attractive candidate for use as single agent and combination therapy. (source: http://pathwaytx.com/product_pipeline.html).
Chemical structure was from https://figshare.com/articles/Chemical_structure_of_VDC-597_/6822143/1